Printer Friendly

U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)

U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
 WEST CONSHOHOCKEN, Pa., Sept. 30 /PRNewswire/ -- U.S. Bioscience, Inc. (AMEX: UBS) today released the following statement:
 A research report issued this morning by Alex. Brown & Sons, Inc., based on an article that appeared in the July issue of The Cancer Letter, stated the firm's decision to lower its investment rating of the stock of U.S. Bioscience, Inc. The article cited in the Alex. Brown report contains inaccurate information concerning the Food and Drug Administration Oncologic Drugs Advisory Committee's (ODAC) recommendation to delay approval of Ethyol.
 The Cancer Letter article noted that the ODAC decision was made because "protective effects had not yet been convincingly established." Although the committee requested completion of the ovarian cancer trial, Chairman Henderson reported ODAC's consensus that the ovarian cancer study provides evidence that toxicity has been significantly decreased, specifically as related to hospitalizations associated with neutropenic fever.
 The article also stated that in a closed session the FDA apparently presented a staff literature review which raised the issue of possible tumor protection. While U.S. Bioscience is not privy to any private discussions within the FDA, and cannot speak to the accuracy of the Cancer Letter comments, the review noted may involve isolated reports, in older literature, of Ethyol uptake in some rodent tumors.
 The ultimate proof of efficacy of any drug is derived from the results of appropriately designed controlled clinical trials in humans. To the knowledge of the company, based upon studies sponsored by U.S. Bioscience, as well as studies by the National Cancer Institute, there have been no data to suggest that Ethyol pretreatment blunts the antitumor effects of chemotherapy or radiation therapy in patients.
 In addition, during Phase II clinical trials, exploring the efficacy of Ethyol/anticancer drug combinations, unexpectedly high tumor response rates have been observed in such tumors as melanoma and lung cancer.
 U.S. Bioscience's New Drug Application (NDA) was built upon the National Cancer Institute's Investigational New Drug Exemption (IND), which contained a large data base of preclinical and clinical information that did not, in the company's opinion, present evidence of tumor protection.
 U.S. Bioscience has prospectively conducted an extensive international program of preclinical research which emphasized the testing of human tumors, including ovarian cancer, melanoma, breast cancer, leukemia and lung cancer.
 This work has been complemented by company-sponsored studies in rodent tumors, as well as the work of independent investigators. All these data are consistent with our previously reported and ongoing clinical observations with no evidence of tumor protection.
 As discussed above, in older literature there have been isolated reports of Ethyol uptake into some rodent tumors. However, even in these reports, given relevant conditions of dose and schedule the protective effect on normal tissue greatly exceeds any effect on tumor.
 We were disappointed to hear of Alex. Brown's change in investment rating of our stock, and believe that careful examination of the facts of the situation does not merit this decision. We would like to point to these comments drawn directly from the research report released this morning by Alex. Brown:
 "We believe that Ethyol either does not protect tumors, or does not do so in a significant way, and we continue to believe that the drug will be approved eventually."
 U.S. Bioscience continues to believe Ethyol is a valuable chemoprotective agent that warrants approval by the FDA.
 Based in West Conshohocken, Pa., U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer drugs, including four products in the late stages of development. One compound, altretamine, is marketed under the name Hexalen(R) in the United States.
 -0- 09/30/92
 CONTACT: Robert I. Kriebel, senior vice president, finance and administration of U.S. Bioscience, 215-832-4503
 (UBS) CO: U.S. BIOSCIENCE, INC. IN: MTC ST: PA -- NY008 -- X284 09/30/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1992
Words:669
Previous Article:KELLOGG USA AND ABC BRING 'ALL THE ME I CAN BE' TO TV
Next Article:TRINITY INDUSTRIES DECLARES QUARTERLY CASH DIVIDEND
Topics:


Related Articles
TRADING OF U.S. BIOSCIENCE STOCK SUSPENDED PENDING CONCLUSION OF FDA COMMITTEE REVIEW
FDA PANEL WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
SCHERING-PLOUGH AND U.S. BIOSCIENCE
U.S. BIOSCIENCE AMENDS NEW DRUG APPLICATION FOR ETHYOL
ODAC WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL; U.S. BIOSCIENCE, INC. TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF ETHYOL
ALZA AND U.S. BIOSCIENCE ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT FOR ETHYOL(R) IN THE UNITED STATES
ALZA CORP.: ETHYOL(R) RECEIVES ADDITIONAL INDICATION FOR USE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
U.S. Bioscience and ALZA Corporation Announce Positive FDA Panel Recommendation for Ethyol(R).
U.S. Bioscience and ALZA Corporation Announce FDA Approval of Ethyol(R) To Reduce Radiation-Induced Xerostomia (Dry Mouth).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters